Eltrombopag Taste Testing in Healthy Adult Volunteers
NCT00487968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2012-03-19
Summary
Based on a need for a pediatric formulation of eltrombopag for the treatment of pediatric thrombocytopenia, this study will help determine the best tasting pediatric formulation of eltrombopag. Healthy adult volunteers who are able to taste bitterness and who do not have a high sensitivity to bitterness will be enrolled. The subjects will evaluate different formulations and rate them based on the bitterness and effectiveness of sweetners. The outcome of this study will help support a decision for a new pediatric formulation of eltrombopag.
Conditions
- Healthy Subjects
- Purpura, Thrombocytopenic, Idiopathic
Interventions
- DRUG
-
eltrombopag
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2007-05-31
Countries
- United States
Study Locations
More Related Trials
-
Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment
NCT00359463 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
NCT00515203 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Romiplostim Treatment for Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome.
NCT04350164 ·Status: COMPLETED
-
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
NCT04371939 ·Status: UNKNOWN ·Phase: PHASE2
-
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
NCT00111475 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Oral Thrombopoietin Receptor Agonist in Pediatric Chronic ITP
NCT05846529 ·Status: UNKNOWN
-
Eltrombopag in Chronic ITP
NCT04102033 ·Status: UNKNOWN ·Phase: PHASE4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
NCT02279173 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients
NCT02403440 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Eltrombopag in Patients With CMML and Thrombocytopenia
NCT02323178 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
NCT02201290 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease
NCT00861601 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.
NCT06531018 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Eltrombopag Phase III Study In Chinese Chronic ITP Patients
NCT01762761 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
NCT00828750 ·Status: COMPLETED ·Phase: PHASE3
-
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
NCT01439321 ·Status: COMPLETED
-
Romiplostim in Chemotherapy-Induced Thrombocytopenia
NCT06201663 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Eltrombopag in Platelet Refractory Thrombocytopenia
NCT01194167 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
NCT00508820 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
NCT02868060 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.
NCT03412188 ·Status: COMPLETED ·Phase: NA
-
A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
NCT01071954 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Romiplostim in Immune Thrombocytopenia (ITP) in the " Real-life " : Result of the French Experience in 72 Adults
NCT01013181 ·Status: COMPLETED
-
Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin
NCT00039858 ·Status: COMPLETED ·Phase: PHASE4
-
A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects
NCT02039076 ·Status: COMPLETED ·Phase: PHASE1